Roy D. Bloom, MD, is Comedical Director of Kidney/Pancreas Transplantation at the University of Pennsylvania in Philadelphia. He is also Assistant Professor of Medicine in the Department of Medicine at the University of Pennsylvania School of Medicine.
Dr. Bloom received his medical degree from the University of Witwatersrand in England. He completed his internships in medicine and general surgery at Johannesburg Hospital in South Africa. He subsequently rotated through several Senior House Officer positions at University Hospitals in the United Kingdom, including Guy’s Hospital, Hammersmith Hospital, Royal Free Hospital, and the St. Phillip’s and St. Paul’s Hospitals, all in London. Dr. Bloom also completed an internship and residency in internal medicine at Albert Einstein Medical Center in Philadelphia. He served fellowships in renal medicine at Brigham and Women’s Hospital and Harvard University in Boston, and at the Hospital of the University of Pennsylvania.
Dr. Bloom is board certified in internal medicine and nephrology by the American Board of Internal Medicine. He serves on several committees including the Patient Care and Education Committee of the American Society of Transplantation, the City Wide Rounds Committee of the National Kidney Foundation’s Delaware Valley Chapter, and the Pharmacy and Therapeutics Committee at the University of Pennsylvania Health System. Dr. Bloom is a member of the American Society of Nephrology, the International Society of Nephrology, and the American Society of Transplant Physicians.
Dr. Bloom is an invited speaker on renal transplantation, and the prevention and treatment of delayed allograft function and delayed graft function. He has written reviews and chapters for books, abstracts, and numerous articles in such journals as Transplantation, American Journal of Kidney Disease, and Kidney International.
Disclosure
Dr. Bloom has received honoraria related to the development of educational materials from SangStat. He has also received honoraria related to speakers’ bureau activities from SangStat.
Dr. Bloom has indicated that he will include the discussion of anti-thymocyte globulin (rabbit) for intra-operative administration to prevent delayed graft function. Anti-thymocyte globulin (rabbit) has not been approved by the FDA for this use in the United States. Dr. Bloom has indicated that he will not include the discussion of products that have not been approved by the FDA for any use.
Kenneth L. Brayman, MD, PhD, FACS, is Director of the Pancreas and Human Islet Transplant Program at the University of Pennsylvania Medical Center and Director of the Renal Transplant Program at the Children’s Hospital of Philadelphia. He is also Associate Professor of Surgery in Medicine and Pediatrics at the University of Pennsylvania School of Medicine.
Dr. Brayman received his medical and doctorate degrees from the University of Pennsylvania School of Medicine. He completed his internship and residency in general surgery at the Hospital of the University of Pennsylvania, where he also served as Chief Resident. Dr. Brayman served his fellowships in transplantation surgery and surgical endoscopy at the University of Minnesota Hospital in Minneapolis.
Dr. Brayman is board certified by the American Board of Surgery and the National Board of Medical Examiners. He serves on numerous committees, and is a member of professional and scientific societies including American Association of Kidney Patients, American Pancreatic Association, and American Society of Transplant Physicians. Dr. Brayman is also a founding member of the International Pancreas and Islet Transplant Association.
Dr. Brayman is principal investigator for 13 current transplant research projects. He is also a coinvestigator for human islet studies.
Dr. Brayman has written more than 275 journal articles, editorials, reviews, and book chapters. He is also a journal manuscript reviewer for eight journals, and serves on the editorial board of Graft. Dr. Brayman has lectured nationally and internationally.
Disclosure
Dr. Brayman has received honoraria related to speakers’ bureau activities from SangStat, Wyeth-Ayerst Laboratories, and Novartis Pharmaceuticals Corporation. He has also received grant support related to research activities from Novartis Pharmaceuticals Corporation, Wyeth-Ayerst Laboratories, and Fujisawa Pharmaceutical Co.
Dr. Brayman has indicated that he will include the discussion of anti-thymocyte globulin (rabbit) for intra-operative administration to prevent delayed graft function. Anti-thymocyte globulin (rabbit) has not been approved by the FDA for this use in the United States. Dr. Brayman has indicated that he will not include the discussion of products that have not been approved by the FDA for any use.
Francis L. Delmonico, MD, is Director of Renal Transplantation at Massachusetts General Hospital and Medical Director of the New England Organ Bank in Newton, Massachusetts. He is also Professor of Surgery at Harvard Medical School.
Dr. Delmonico received his medical degree from George Washington University. He completed his internship and residency in surgery at Medical College of Virginia, where he also served as Chief Resident. Dr. Delmonico served his clinical and research fellowships in surgery/transplantation at Massachusetts General Hospital.
Dr. Delmonico is board certified by the American Board of Surgery and the National Board of Medical Examiners. He serves on several committees including the American Society of Transplantation Board of Directors, American Society of Transplant Surgeons, and the National Kidney Foundation of Massachusetts Medical Advisory Board. Dr. Delmonico is also a member of numerous professional and scientific societies.
Dr. Delmonico has written more than 100 journal articles, editorials, reviews, monographs, and book chapters. He also serves on the editorial board of 13 journals. Dr. Delmonico lectures nationally and internationally.
Disclosure
Dr. Delmonico has received honoraria related to formal advisory activities from Genzyme Data Safety Monitoring Board.
Dr. Delmonico has indicated that his presentation will not include the discussion of unlabeled uses of commercial products or products that have not yet been approved by the FDA for use in the United States for any purpose.
Arthur J. Matas, MD, is Professor of Surgery and Director of Renal Transplant Service at the University of Minnesota in Minneapolis. He is also Compliance Officer and an attending surgeon at University of Minnesota. Dr. Matas is a consultant for the Minnesota Veterans Administration.
After receiving his medical degree from the University of Manitoba College of Medicine,
Dr. Matas completed his internship and residency in surgery and his fellowship in transplantation at University of Minnesota Hospitals.
Dr. Matas is board certified in surgery. He serves on the American Society of Transplant Physicians Awards Committee, the International Society for Organ Sharing, ASTS Nominations Committee, and ASTS Informatics and Data Management Committee. He is a member of several professional societies including American Society of Nephrology, International Society of Transplantation, and American Society of Transplant Physicians.
Dr. Matas is a member of numerous editorial boards including Clinical Transplantation, Transplantation, Graft, and Nephrology News and Issues. He has written more than 400 articles and lectures nationally and internationally.
Disclosure
Dr. Matas has received honoraria related to formal advisory activities from Novartis Pharmaceuticals Corporation. He has also received honoraria related to the development of educational materials from SangStat. Dr. Matas has received grant support related to research activities from Roche Pharmaceuticals, Novartis Pharmaceuticals Corporation, Fujisawa Pharmaceutical Co., Wyeth-Ayerst Laboratories, and SangStat.
Dr. Matas has indicated that his presentation will not include the discussion of unlabeled uses of commercial products or products that have not yet been approved by the FDA for use in the United States for any purpose.
Back